Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Frontiers In Cell And Developmental Biology 2016, 4: 64. PMID: 27446916, PMCID: PMC4917534, DOI: 10.3389/fcell.2016.00064.Peer-Reviewed Original ResearchProstate cancerTumor initiating cellsHuman immune systemHumanized miceTherapeutic responsePersonalized therapeutic responseAdaptive T cellsPrimary prostate cancerPatient-derived organoidsPersonalized medicine approachPCa microenvironmentSelective engraftmentImmunotherapy approachesCommon malignancyCancer deathSpecific therapyImmune cellsDisease progressionCancer precision medicineCommon causeT cellsChimeric antigenPatient-specific therapiesMouse modelTherapy resistancePatient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential.
Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. DOI: 10.1200/jco.2016.34.2_suppl.252.Peer-Reviewed Original ResearchResidual tumor fociMesenchymal growth factorsRadical prostatectomy specimensClonal heterogeneityTumor initiating cellsProstate cancer organoidsMechanisms of resistanceMetastatic PCPC progressionTherapeutic alternativeTumor fociNormal epitheliumPatient stem cellsProstatectomy specimensMolecular alterationsPotential efficacyCancer organoidsSelf-renewal capacityInitiating cellsGrowth factorBiologic responseEarly passagesGrowth inhibitionStem cellsEpigenetic alterations